






## Article

# Measuring the Metabolic Evolution of Glioblastoma throughout Tumor Development, Regression, and Recurrence with Hyperpolarized Magnetic Resonance

Travis C. Salzillo <sup>1</sup>, Vimbai Mawoneke <sup>1</sup>, Joseph Weygand <sup>2</sup>, Akaanksh Shetty <sup>1</sup>, Joy Gumin <sup>3</sup>, Niki M. Zacharias <sup>4</sup>, Seth T. Gammon <sup>1</sup>, David Piwnica-Worms <sup>1</sup>, Gregory N. Fuller <sup>5</sup>, Christopher J. Logothetis <sup>6</sup>, Frederick F. Lang <sup>3</sup> and Pratip K. Bhattacharya <sup>1,\*</sup>

<sup>1</sup> Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; tcsalzillo@mdanderson.org (T.C.S.); vmawoneke@brynmawr.edu (V.M.); ashetty612@gmail.com (A.S.); STGammon@mdanderson.org (S.T.G.); dpiwnica-worms@mdanderson.org (D.P.-W.)

<sup>2</sup> Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA; joseph.weygand@moffitt.org

<sup>3</sup> Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; jgumin@mdanderson.org (J.G.); flang@mdanderson.org (F.F.L.)

<sup>4</sup> Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; NMZacharias@mdanderson.org

<sup>5</sup> Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; gfuller@mdanderson.org

<sup>6</sup> Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; clogothe@mdanderson.org

\* Correspondence: pkbhattacharya@mdanderson.org; Tel.: +1-713-454-9887



**Citation:** Salzillo, T.C.; Mawoneke, V.; Weygand, J.; Shetty, A.; Gumin, J.; Zacharias, N.M.; Gammon, S.T.; Piwnica-Worms, D.; Fuller, G.N.; Logothetis, C.J.; et al. Measuring the Metabolic Evolution of Glioblastoma throughout Tumor Development, Regression, and Recurrence with Hyperpolarized Magnetic Resonance. *Cells* **2021**, *10*, 2621. <https://doi.org/10.3390/cells10102621>

Academic Editors: Doug Brooks, Alexandra Sorvina and Shane Hickey

Received: 20 August 2021

Accepted: 23 September 2021

Published: 1 October 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Abstract:** Rapid diagnosis and therapeutic monitoring of aggressive diseases such as glioblastoma can improve patient survival by providing physicians the time to optimally deliver treatment. This research tested whether metabolic imaging with hyperpolarized MRI could detect changes in tumor progression faster than conventional anatomic MRI in patient-derived glioblastoma murine models. To capture the dynamic nature of cancer metabolism, hyperpolarized MRI, NMR spectroscopy, and immunohistochemistry were performed at several time-points during tumor development, regression, and recurrence. Hyperpolarized MRI detected significant changes of metabolism throughout tumor progression whereas conventional MRI was less sensitive. This was accompanied by aberrations in amino acid and phospholipid lipid metabolism and MCT1 expression. Hyperpolarized MRI can help address clinical challenges such as identifying malignant disease prior to aggressive growth, differentiating pseudoprogression from true progression, and predicting relapse. The individual evolution of these metabolic assays as well as their correlations with one another provides context for further academic research.

**Keywords:** magnetic resonance imaging; hyperpolarization; nuclear magnetic resonance; glioblastoma; metabolism; radiation therapy; tumor development; tumor regression; tumor recurrence



**Copyright:** © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

In 2020, an estimated 87,240 new cases of primary brain and other central nervous system (CNS) tumors were diagnosed in the United States with 25,800 expected to be malignant [1]. WHO grade IV glioblastoma (GBM) is the most common malignant brain tumor in adults, representing 48.3% of the cases as well as the most deadly with 5-year survival rates of merely 6.8%. Despite standard-of-care treatment with surgery, radiotherapy, and temozolomide chemotherapy, prevailing therapies remain palliative, and tumors are almost always recurrent and lead to median survival times of approximately 15 months [2]. Alternative therapies, both FDA-approved and experimental, have shown little to no

improvement on overall survival, as factors such as relatively average mutational load, tumor heterogeneity, and molecular filtration by the blood-brain barrier challenge drug development for this disease [3]. This failure to make major inroads points to the need for alternative approaches in the management of this disease.


Imaging has been used to inform anatomic-based intervention by determining the extent of involvement of the tumor, its proximity to functional regions, and monitoring recurrence. Advanced imaging techniques provide the opportunity to examine the cancer in alternate biologic domains that may determine therapeutic vulnerability in specific subsets. Such a strategy would complement the prevailing anatomic-based classifiers and could potentially address several clinical challenges when it comes to improving patient survival and optimizing drug discovery. These include the early detection and discrimination of malignant disease, rapid assessment of treatment efficacy (including distinguishing pseudoprogression from true progression), and prediction of tumor recurrence. Molecular imaging, especially by probing tumor metabolism, has shown great promise in augmenting conventional clinical imaging for the diagnosis, prognosis, and treatment monitoring of brain tumors [4,5].

Hyperpolarized magnetic resonance (MR) is one such technique that has found success over the past several years for diagnosing a number of tumor types [6] and measuring their response to therapy [7,8]. Pyruvate is the most commonly used hyperpolarized substrate due to its relatively long signal enhancement lifetime and central role in tumor metabolism via the Warburg effect [9,10]. Compelling findings from the numerous preclinical studies with this substrate have justified the initiation of several clinical trials for the use of hyperpolarized pyruvate in multiple tumor sites including brain cancer, which has produced human data from healthy volunteers [11–13] and glioma patients [14–17]. Given the current advances, there is a strong likelihood that hyperpolarized pyruvate MR will be adopted in the clinic with FDA approval for metabolic imaging of brain cancer, and protocols for integrating this technique into the clinical workflow are underway [18].

There is still much to be explored to determine the specific clinical implementations of hyperpolarized MR to produce significant impact in the treatment of brain tumors. Existing preclinical studies do a thorough job of elucidating differences in pyruvate utilization between tumors and healthy brain [19–23] or between untreated and treated tumors [24–27], but they only do so at one point during development or with one pre- and post-treatment measurement. Tumor metabolism is heterogeneous and evolves over the course of tumor development suggesting that the time-point of the measurement can significantly impact the results [28–30]. Following treatment, metabolism is similarly dynamic as it responds to therapeutic insults before gaining resistance or regrowing. This complex metabolic trajectory cannot be captured with one post-treatment measurement alone. Therefore, we sought to implement serial hyperpolarized MRS measurements at multiple time-points over the course of tumor growth and treatment regimen to elucidate this metabolic evolution. In vivo hyperpolarized pyruvate-to-lactate conversion values were determined at multiple time-points throughout three stages of tumor progression (development, regression following radiotherapy and recurrence to the point of relapse). Additionally, the novel use of hyperpolarized MRS to assess brain tumor recurrence, which is an unfortunate and inevitable reality for most GBM patients, could improve patient survival by informing physicians when additional treatment is necessary before the tumor aggressively regrows [31,32].

The purpose of this study was to compare hyperpolarized pyruvate-to-lactate conversion values from the serial hyperpolarized MRS experiments with tumor volume changes that were acquired with anatomic MRI during each stage of tumor progression (Figure 1). This was carried out to demonstrate the value of adding hyperpolarized MR to conventional imaging protocols by addressing several challenges commonly encountered in the clinical setting. Furthermore, we sought to form a more complete picture of the metabolic events occurring during tumor progression by performing metabolomics with nuclear magnetic resonance (NMR) spectroscopy and protein expression assays with immuno-

histochemistry (IHC) on ex vivo samples at multiple time-points, and investigating the interrelationships of each of these measurements over the entire course of tumor lifetime.



**Figure 1.** Anatomic and metabolic imaging of tumor-bearing mice over time. Tumor volume (A), imaged with T2-weighted MRI, and pyruvate-to-lactate conversion (B), measured with hyperpolarized MRS, is displayed at the end of tumor development (Day 34), end of tumor regression (Day 55), and at the point of relapse (Day 68) in the same mouse.

## 2. Materials and Methods

### 2.1. Resource Availability

#### 2.1.1. Materials Availability

This study did not generate new unique reagents.

#### 2.1.2. Data and Code Availability

The dataset containing all tumor volume, nLac, metabolite pool size, and protein expression values generated during this study as well as the MATLAB code used to calculate nLac from raw hyperpolarized  $^{13}\text{C}$  spectral data are available at <http://dx.doi.org/10.17632/mf5f93t3kn.1> (accessed on 23 September 2021).

### 2.2. Experimental Model and Subject Details

#### 2.2.1. Cell Lines

GSC 8-11: Glioma sphere-forming cells (GSC) 8-11 were isolated from surgical sample from a female patient, following written consent and approval by the institutional review board of The University of Texas M. D. Anderson Cancer Center, and have been characterized in the literature [33]. As reported in the literature [34,35], cells were grown in Neurosphere Media containing DMEM/F12 (Corning, Corning, NY, USA) with B27 ( $\times 1$ , Thermo Fisher Scientific, Waltham, MA, USA), bFGF (20 ng/mL, Millipore Sigma, St. Louis, MO, USA), and EGF (20 ng/mL, Millipore Sigma, St. Louis, MO, USA) at a temperature of 37 °C. These cells were authenticated by the MDACC Cell Authentication Core (<https://www.mdanderson.org/research/research-resources/core-facilities/cytogenetics-and-cell-authentication-core.html>).

### 2.2.2. Animals

Mice: Five-week-old athymic nude mice (Experimental Radiation Oncology, MDACC, Houston, TX, USA) were used for *in vivo* studies. Mice were housed together in a sterilized facility with 5 to a cage, so only females were used as they are less prone to fighting with each other. Mice received standard feed and water and were inspected for health daily. A guide-screw system was used for injection to allow for consistent placement of intracranial xenografts as described in literature [36]. A 2.6 mm long guide screw with a 0.5 mm channel bored through its center was drilled into the skull directly over the caudate nucleus. After the mice had recovered for 2 weeks,  $5 \times 10^5$  GSC 8-11 cells were suspended in 3  $\mu$ L of phosphate-buffered saline (PBS) and injected stereotactically through the bore of the guide screw over a period of five minutes. After injection, a stylet was placed in the bore of the screw to close the system and prevent tissue from growing inside. Control animals were prepared in the same manner except that PBS absent of GSCs was injected. All procedures were performed in accordance with regulations of the Institutional Animal Care and Use Committee (IACUC) of the University of Texas MD Anderson Cancer Center.

## 2.3. Method Details

### 2.3.1. Experimental Overview

Following the intracranial implantation of patient-derived glioma sphere-forming cells (GSC), the anatomic and metabolic properties of this GBM model were interrogated at several time-points during three stages of tumor progression: tumor development, regression following radiotherapy, and eventual recurrence. Mice were split into three cohorts: untreated tumor-bearing mice, treated tumor-bearing mice ( $2 \times 5$  Gy radiotherapy), and control mice. Anatomic growth and shrinkage were studied *in vivo* with T1-weighted, T2-weighted, and fluid-attenuated  $^1\text{H}$  MRI. Real-time conversion of injected pyruvate to lactate was measured in the tumor *in vivo* with hyperpolarized  $^{13}\text{C}$  MRS. *Ex vivo* metabolite pool sizes and protein expression were determined with NMR spectroscopy and IHC, respectively. All measurements were acquired within  $\pm 1$  day of their nominal time-point.

### 2.3.2. Tumor Radiotherapy

Tumor-bearing mice in the treatment cohort underwent radiotherapy to attenuate tumor growth. On Days 25 and 27, the mice were imaged and treated with 5 Gy whole-brain irradiation on the X-RAD SmART small animal irradiator (Precision X-ray, North Branford, CT, USA). A cone-beam CT was acquired for treatment planning, and irradiation was executed with two opposing fields of 2.5 Gy each.

### 2.3.3. Anatomic Magnetic Resonance Imaging

Tumor anatomy was visualized with MRI on a Bruker 7 T preclinical scanner (Bruker Biospin MRI GmbH, Ettlingen, Germany) every 3 days. Rapid Acquisition with Relaxation Enhancement (RARE) T1-weighted (T1-w), T2-weighted (T2-w), and fluid-attenuated inversion recovery (FLAIR)  $^1\text{H}$  pulse sequences were implemented. A 35 mm RF volume coil (Bruker) was used to acquire the images. The following pulse sequences and parameters were used: coronal, sagittal, and axial T2-w (FA =  $90^\circ$ , TE = 6.5 ms, TR = 1500 ms, BW = 75 kHz, Matrix =  $256 \times 192$ , FOV = 25 mm  $\times$  25 mm (axial 20 mm  $\times$  20 mm), NEX = 4, Slice Thickness = 0.75 mm, Slice Gap = 0.25 mm, RARE Factor = 12); axial T2-w FLAIR (FA =  $90^\circ$ , TE = 48 ms, TR = 10,000 ms, TI = 2000 ms, BW = 38 kHz, Matrix =  $256 \times 192$ , FOV = 20 mm  $\times$  20 mm, NEX = 3, Slice Thickness = 0.75 mm, Slice Gap = 0.25 mm, RARE Factor = 10, Fat Suppression on); axial T1-w (FA =  $90^\circ$ , TE = 57 ms, TR = 3000 ms, BW = 85 kHz, Matrix =  $256 \times 192$ , FOV = 20 mm  $\times$  20 mm, NEX = 3, Slice Thickness = 0.75 mm, Slice Gap = 0.25 mm, RARE Factor = 4, Fat Suppression on).

### 2.3.4. Tumor Volume Measurements

DICOM images from the T1-w, T2-w, and FLAIR pulse sequences were imported into 3D Slicer software [37]. Tumors were segmented on each slice of the coronal, sagittal,

and axial T2-w images. T1-w and FLAIR images were used to confirm tumor boundaries and differentiate tumor tissue from surrounding edema and cerebral spinal fluid. Volume in each plane of the T2-w images was calculated by multiplying the number of voxels within the tumor segmentation by the spatial dimensions of the voxels. The calculated volumes from each of the three T2-w imaging planes were averaged together to give the final volume measurement of the tumor. Plane-averaged tumor volumes from at least 5 mice were averaged at each time-point.

### 2.3.5. Hyperpolarized Sample Preparation

[1-<sup>13</sup>C]pyruvic acid (Millipore Sigma, St. Louis, MO, USA) was doped with Ox063 trityl radical (Oxford Instruments, Abingdon, UK) to 15 mM concentration. An amount of 20 µL of this solution was mixed with 0.4 µL of 50 mM Gd<sup>3+</sup> (Bracco Diagnostics, Monroe Township, NJ, USA). This solution was placed in a DNP HyperSense (Oxford Instruments, Abingdon, UK) to polarize for approximately 1 h under microwave irradiation at 94,100 GHz. An average signal enhancement of 20,000-fold was achieved. Once the sample was prepared, it was rapidly heated and dissolved in 4 mL buffer comprised of 40 mM 2-Amino-2-(hydroxymethyl)-1,3-propanediol (TRIS; Millipore Sigma, St. Louis, MO, USA), 80 mM NaOH, 0.1 g/L ethylenediaminetetraacetic acid (EDTA; Millipore Sigma, St. Louis, MO, USA), and 50 mM NaCl. This solution had a final [1-<sup>13</sup>C]pyruvic acid concentration of 80 mM which was then injected intravenously through the tail vein of the mouse.

### 2.3.6. <sup>13</sup>C Magnetic Resonance Spectroscopy

A 72 mm <sup>1</sup>H volume coil (Bruker Biospin MRI GmbH, Ettingen, Germany) was used to acquire anatomic images for accurate region of interest (ROI) placement for spectroscopy. A <sup>13</sup>C transmit/receive surface coil (ID: 35 mm; Doty Scientific Inc., Columbia, SC, USA) was placed above the skull, directly over the tumor. A <sup>13</sup>C slice-selective, pulse-acquired spectroscopy sequence was prepared in which a single slice in the transverse plane was placed over the tumor (Slice Thickness = 6 mm, FA = 25°, pulse length = 0.48 ms, BW = 5 kHz, readout points = 2048, NEX = 1, reference frequency = 75.515 MHz; FID was acquired 0.2 ms following transmit pulse). Spectra were acquired every 2 s for 2 min to detect [1-<sup>13</sup>C]pyruvate and its lactate product.

### 2.3.7. Pyruvate-to-Lactate Measurements

The time-resolved stack of <sup>13</sup>C MR spectra was imported into MATLAB (The MathWorks, Inc. Natick, MA, USA). A freely-available MATLAB script courtesy of the Hyperpolarized MRI Technology Resource Center (Hyperpolarized-MRI-Toolbox. Available online at: <https://github.com/LarsonLab/hyperpolarized-mri-toolbox>, doi:10.5281/zenodo.1198915) was used to analyze the spectra. This script was adapted so that each of the individual spectra in the time-resolved stack could be phase- and baseline-corrected individually, rather than as a sum. Following these corrections, the pyruvate and lactate peaks were integrated (full-width, quarter-max), and the integral values were summed across all spectra in the time-resolved stack. The metric for pyruvate-to-lactate conversion, denoted as nLac, was then calculated using these values as the ratio of lactate:lactate + pyruvate. The nLac measurements from at least 5 tumor-bearing mice were averaged at each time-point. Additionally, *N* = 3 nLac measurements from control mice were averaged and compared with tumor-bearing mice at these time-points.

### 2.3.8. Brain Sample Excision

Any excisions from mice who received hyperpolarized pyruvate injections were delayed such that there was one day between the hyperpolarized pyruvate injection and brain excision. This was done to ensure that tumor metabolism returned to steady state after being perturbed by the large pyruvate bolus. Mice were euthanized and the bolt and top of the skull were carefully removed to expose the brain. The optical tracts were severed,

and the intact brain was excised. For samples to be processed for immunohistochemistry (IHC) analysis, the entire brain was placed and fixed in a vial containing 10% formalin.

For samples to be processed for nuclear magnetic resonance (NMR) spectroscopy, incisions were made along the longitudinal and transverse fissures. The tissue within the left cerebral hemisphere (which contained the GSC injection site) was isolated from the remainder of the brain (which included the olfactory bulb, right cerebral hemisphere, and cerebellum). The isolated tissue was flash-frozen in liquid nitrogen and transferred to a freezer at  $-80\text{ }^{\circ}\text{C}$ . This process was executed as quickly as possible to preserve cellular metabolism, and the same volume of tissue was collected across all time-points, regardless of tumor size.

### 2.3.9. Sample Preparation for Metabolite Extraction

Metabolites were extracted from ex vivo samples as described in the literature [38]. Frozen samples were pulverized and weighed. The tissue particles were transferred to a conical centrifuge tube containing 2 mL of methanol, 1 mL of water, and 0.5 mL of lysing beads. The samples were vortexed, flash-frozen, and thawed for 3 cycles to lyse the cells. The samples were then centrifuged at  $4\text{ }^{\circ}\text{C}$  for 10 min, and the supernatant, containing water, methanol, and dissolved metabolites, was extracted. The methanol was evaporated under reduced pressure using a rotary evaporator, and the remaining solvent was freeze-dried using a lyophilizer. The dried product was dissolved in 600  $\mu\text{L}$  of deuterium oxide, 36  $\mu\text{L}$  of phosphate-buffered saline, and 4  $\mu\text{L}$  of 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS-d6) as the NMR reference standard (500  $\mu\text{M}$  in solution). The final 640  $\mu\text{L}$  solution was transferred to a 5 mm NMR tube. All supplies (deuterium oxide, DSS, phosphate buffer) were purchased from Isotec Sigma Aldrich and used without further purification.

### 2.3.10. Nuclear Magnetic Resonance Spectroscopy

NMR spectra were obtained using a Bruker AVANCE III HD<sup>®</sup> NMR scanner (Bruker Biospin MRI GmbH, Ettingen, Germany) at a temperature of 298 K. The spectrometer operates at a  $^1\text{H}$  resonance frequency of 500 MHz and is endowed with a triple resonance ( $^1\text{H}$ ,  $^{13}\text{C}$ ,  $^{15}\text{N}$ ) Prodigy BBO cryogenic temperature probe with a Z-axis shielded gradient for increased sensitivity. A pre-saturation technique was implemented for water suppression. The spectra were obtained with a  $90^{\circ}$  pulse of length 12  $\mu\text{s}$ , a scan delay  $t_{\text{rel}}$  of 6 s, a 10,240 Hz spectral width, and an acquisition time  $t_{\text{max}}$  of 1.09 s (16,000 complex points). A total of 256 scans are collected and averaged for each spectrum, which results in a total scan time of 33 min. Here,  $t_{\text{rel}} + t_{\text{max}}$  is nearly 8 s so that it exceeds  $3T_1$  for the metabolites observed. The time domain signal is apodized using an exponential function.

### 2.3.11. Metabolite Pool Size Measurements

The raw FID files from the spectrometer were imported into MestreNova software (Mestrelab Research, A Coruña, Spain) where they were Fourier transformed into frequency domain spectra. The spectra were manually phase-corrected to form Lorentzian peak shapes and manually baseline-corrected prior to peak integration, and the DSS reference peak was set to 0 ppm. The processed spectra were exported to Chenomx NMR Suite 8.1 software (Chenomx Inc., Edmonton, Canada) where the peaks were identified by matching them to spectral models of metabolites contained in the database. The identified peaks were integrated in MestreNova, and the peak areas were normalized to the peak area of DSS. As described in the literature [39], these values were further normalized to the mass of the pulverized tissue (in mg) and converted to metabolite concentrations (in  $\mu\text{M}$ ) by implementing the Beer–Lambert law. The final values were reported as  $\mu\text{M}/\text{mg}$ . Similar to the nLac measurements, there were  $N = 5$  groups of measurements for the tumors and  $N = 3$  groups of measurements for the healthy brain controls at each time-point.

### 2.3.12. Sample Preparation for Immunohistochemistry

Mice were euthanized by intracardiac perfusion of PBS and 4% paraformaldehyde. Brains were removed, fixed in 10% formalin for at least 24 h and embedded in paraffin. Sections (5  $\mu$ m) were cut for immunohistochemical analysis.

### 2.3.13. Immunohistochemistry

Sections of formalin-fixed paraffin-embedded mouse brain specimens were deparaffinized with xylene and rehydrated through a graded alcohol series, followed by distilled water and PBS. The slides were processed for antigen retrieval by pressure cooker in citrate buffer (pH 6.0) for 20 min. The slides were incubated overnight with the mouse antihuman MCT1 antibody (Santa Cruz Biotechnology, Dallas, TX, USA) at 1:200 dilution and rabbit antihuman LDH-A antibody (Abcam, Cambridge, MA, USA) at 1:100 dilution. For the MCT1 immunostaining, slides were incubated with Mouse Ig Blocking Reagent (Vector Laboratories, Burlingame, CA, USA) to reduce endogenous mouse Ig staining. The slides were rinsed with PBS and incubated with Anti-rabbit Poly-HRP-IgG (Leica Biosystems, Buffalo Grove, IL, USA) and Polymer Anti-Mouse IgG reagent (Leica Biosystems, Buffalo Grove, IL, USA) and visualized with 3,3'-Diaminobenzidine (DAB). The slides were counterstained with hematoxylin, dehydrated and coverslipped.

### 2.3.14. Protein Expression Measurements

The 40 $\times$  images (1360  $\times$  1024 pixels) of MCT1 and LDH-A stains were loaded into the FIJI package of ImageJ [40]. Color deconvolution was performed [41] to extract the DAB stain from the image. These DAB images were thresholded so that DAB signal was set to 1 and everything else was set to 0. Three nonoverlapping, uniformly-sized ROI (340  $\times$  256 pixels) were randomly placed in the tumor and one ROI outside the tumor as a background measurement. The percent area of DAB stain was calculated in these ROI (number of DAB-positive pixels divided by number of pixels in ROI). Percent area from the background ROI was subtracted from each of the tumor ROI which were then averaged together to produce the final metric for protein expression in that image. Average percent area from each image at a time-point were further averaged together to describe protein expression over the course of tumor development.

## 2.4. Quantification and Statistical Analysis

All statistical analysis was conducted using GraphPad Prism 8 (GraphPad Software, La Jolla, CA, USA). All measurements are reported as the mean value  $\pm$  standard deviation, and error bars in the figures represent standard deviation. *N* represents the sample size for each group as a single number or range of values.

### 2.4.1. Median Survival Time

Kaplan–Meier analysis was used to compare the median survival of untreated (*N* = 102) and treated (*N* = 59) tumor-bearing mice. Specifically, the Mantel–Cox logrank test was used to test for significant differences between median survival times, and the logrank method was used to calculate the hazard ratio.

### 2.4.2. In Vivo Tumor Volume Measurements

In untreated tumors during development, average volume at each time-point (*N* = 5–10) was compared with baseline average volume measured on Day 5 (*N* = 6). In treated tumors following radiotherapy, average volume at each time-point (*N* = 5–10) was compared with average volume at time of treatment on Day 26 (*N* = 8) as well as to maximum average volume (*N* = 10). Volume data were log-transformed to correct for heteroscedasticity and tested for significant differences using ordinary one-way ANOVA and follow-up Fisher's Least Significant Differences tests (*p* < 0.05) where *p* is the probability value.

Repeated measures of individual tumor volume values in treated tumor-bearing mice were further analyzed using mixed-effects analysis with the Geisser–Greenhouse correction as an additional check for significant changes.

#### 2.4.3. In Vivo Pyruvate-to-Lactate Measurements

During tumor development, average nLac of untreated tumors ( $N = 5$ ) were compared with average nLac of controls ( $N = 3$ ) at each time-point. In treated tumors, average nLac at each time-point ( $N = 5$ –8) was compared with average nLac at all prior time-points as well as to average nLac of untreated tumors and controls on Days 28 and 34. Statistical significance was determined using ordinary one-way ANOVA and follow-up Fisher’s Least Significant Difference tests ( $p < 0.05$ ).

Repeated measures of individual nLac values in treated tumor-bearing mice were further analyzed using mixed-effects analysis with the Geisser–Greenhouse correction as an additional check for significant changes.

#### 2.4.4. Ex Vivo Metabolite Pool Size Measurements

During tumor development, average metabolite pool sizes of untreated tumors ( $N = 5$ –7) were compared with average metabolite pool sizes of normal brain tissue controls ( $N = 3$ ) at each time-point. In treated tumors, average metabolite pool sizes at each time-point ( $N = 5$ ) were compared with average metabolite pool sizes at all prior time-points as well as to average metabolite pool sizes of untreated tumors and controls on Days 28 and 34. Statistical significance was determined using ordinary one-way ANOVA and follow-up Fisher’s Least Significant Difference tests. Due to the large number of comparisons (each set of comparisons made for 26 metabolites), the false discovery rate was controlled using the two-stage step-up method of Benjamini, Krieger and Yekutieli ( $Q < 0.05$ ).

#### 2.4.5. Ex Vivo Protein Expression Measurements

During tumor development, average background-subtracted percent stained area (MCT1 and LDH-A) from 3 ROI in each  $40\times$  capture ( $N = 1$ –5) from untreated tumors was compared at each time-point as well as with healthy brain controls. Statistical significance was determined using ordinary one-way ANOVA and follow-up Fisher’s Least Significant Difference tests ( $p < 0.05$ ).

### 3. Results


#### 3.1. Radiotherapy Significantly Extends Survival of GSC 8-11 Tumor-Bearing Mice

In mice implanted with GSC 8-11, a patient-derived GBM cell line, survival time was compared between untreated mice and mice treated with  $2 \times 5$  Gy of whole-brain irradiation on Days 25 and 27 using Kaplan–Meier analysis (Figure 2). Median survival was significantly increased in treated tumor-bearing mice compared with untreated mice (88 vs. 34 days,  $p < 0.0001$ ). There was over a 250% increase in median survival time, which produced a hazard ratio of 4.6. Therefore, the radiotherapy dose of  $2 \times 5$  Gy was effective at extending the survival of tumor-bearing mice, allowing for tumor regression and recurrence to be assessed in the radiotherapy treated mouse cohort.


#### 3.2. Tumor Volume Increases during Development but Does Not Significantly Change throughout Regression or Recurrence

**Tumor Development (Day 1–34):** Following GSC implantation, average tumor volume was assessed every 3–4 days with T1-weighted, T2-weighted, and fluid-attenuated MRI (Figure 3). An initial baseline volume of  $1.4 \pm 0.5 \text{ mm}^3$  was measured on Day 5. Average tumor volume experienced exponential growth ( $R^2 = 0.60$ ), increasing slowly at first before rapidly expanding on Day 21 where it nearly tripled from the prior time-point to a value of  $15.2 \pm 9.7 \text{ mm}^3$ . At a value of  $3.5 \pm 0.9 \text{ mm}^3$ , average tumor volume was significantly increased by Day 10 compared with baseline volume ( $p = 0.0282$ ). By the endpoint of tumor development (Day 34), average untreated tumor volume was  $88.6 \pm 56.3 \text{ mm}^3$ .





**Figure 2.** Radiotherapy significantly extends survival of GSC 8-11 tumor-bearing mice. Median survival of treated mice (green line) was significantly higher compared with untreated mice (blue line) (88 vs. 34 days,  $p < 0.0001$ ). The hazard ratio of untreated-to-treated mice was 4.6. Mice that were euthanized on specific time-points for ex vivo experiments as well as those that died from non-tumor-related causes were censored (black markers). Survival was calculated using Kaplan–Meier analysis. Significant differences between the curves were calculated with the Mantel–Cox logrank test and the hazard ratio using logrank approach.



**Figure 3.** Tumor volume increases during development but does not significantly change throughout regression or recurrence. Average tumor volume, measured from anatomic MRI, is plotted as a function of time in untreated (blue squares) and treated (green triangles) mice. Error bars represent standard deviation (not visible before Day 21 due to scale of Y-axis). These values were log-transformed to correct for heteroscedasticity and tested for significant differences using ordinary one-way ANOVA and follow-up Fisher’s Least Significant Differences tests. Comparisons that produced  $p < 0.05$  were deemed significant. \*  $p < 0.05$ .

**Tumor Regression (Day 25–48):** Following radiotherapy, tumor volume was measured on Days 26, 30, 34, and every 7 days thereafter (Figure 3). On Day 34, average treated tumor volume was significantly increased compared with its initial value on Day 26 ( $82.9 \pm 66.6$  vs.  $26.0 \pm 14.9$  mm<sup>3</sup>,  $p = 0.0090$ ). Average treated tumor volume then began to decrease to a minimum of  $57.3 \pm 51.2$  mm<sup>3</sup> on Day 48 although no significant differences were observed compared with initial treated tumor volume on Day 26 or maximum treated tumor volume on Day 34.


**Tumor Recurrence (Day 48–72):** The same group of mice were imaged every 7 days throughout tumor recurrence (Figure 3). After reaching a minimum of  $57.3 \pm 51.2$  mm<sup>3</sup> on Day 48, average treated tumor volume monotonically increased to a final volume of  $72.3 \pm 57.0$  mm<sup>3</sup> on Day 72. While this value was significantly higher than initial treated tumor volume on Day 26 ( $p = 0.0396$ ), neither grouped ANOVA analysis nor mixed-effects analysis of individual repeated measures revealed any significant increases in treated tumor volume throughout tumor recurrence.

### 3.3. *In Vivo* Pyruvate-to-Lactate Conversion Is Significantly Altered throughout Tumor Development, Regression, and Recurrence

**Tumor Development (Day 1–34):** Using hyperpolarized <sup>13</sup>C MRS, pyruvate-to-lactate conversion, quantified by nLac, was measured in tumor-bearing mice and control mice every 7 days with an extra measurement on Day 10 to capture early tumor dynamics (Figure 4A). The nLac is defined as the ratio of lactate:lactate + pyruvate where lactate and pyruvate are the area-under-the-curve values calculated from the time-resolved <sup>13</sup>C spectra. Starting on Day 14, average nLac was significantly increased in tumor-bearing mice compared with control mice ( $0.39 \pm 0.16$  vs.  $0.26 \pm 0.10$ ,  $p = 0.0273$ ) which persisted throughout the remaining time-points in tumor development. In tumor-bearing mice, average nLac increased with a significantly nonzero slope ( $0.0069$  days<sup>-1</sup>,  $p = 0.0006$ ) to a final value of  $0.45 \pm 0.09$  on Day 34. In contrast, average nLac in control mice remained constant across all time-points (slope =  $0.0005$  days<sup>-1</sup>,  $p = 0.7674$ ), at an average value of  $0.26 \pm 0.07$ .

**Tumor Regression (Day 25–48):** Following radiotherapy, hyperpolarized MRS experiments were conducted in treated mice starting on Day 28 and every 7 days thereafter (Figure 4B). Average nLac decreased following radiotherapy and was significantly decreased in treated tumor-bearing mice on Day 48 compared with treated tumor-bearing mice on Days 28 ( $0.31 \pm 0.05$  vs.  $0.44 \pm 0.09$ ,  $p = 0.0080$ ), 34 ( $0.31 \pm 0.05$  vs.  $0.49 \pm 0.08$ ,  $p = 0.0004$ ), and 41 ( $0.31 \pm 0.05$  vs.  $0.43 \pm 0.07$ ,  $p = 0.0186$ ). Additionally, average nLac was significantly decreased in treated tumor-bearing mice on Day 48 compared with untreated tumor-bearing mice on Days 28 ( $0.31 \pm 0.05$  vs.  $0.48 \pm 0.06$ ,  $p = 0.0008$ ) and 34 ( $0.31 \pm 0.05$  vs.  $0.45 \pm 0.09$ ,  $p = 0.0063$ ). Lastly, of the tumor-bearing mice which had initial values of nLac < 0.4 immediately following treatment (on Day 28 or 34), 0/3 died from tumor burden by the Day 94 endpoint of the study. In contrast, 5/7 treated tumor-bearing mice with initial values of nLac > 0.4 died from tumor burden before reaching the Day 94 endpoint.

**Tumor Recurrence (Day 48–72):** Hyperpolarized MRS experiments were performed on the same group of mice every 7 days throughout tumor recurrence (Figure 4B). Average nLac linearly increased with a significantly nonzero slope ( $0.0067$  days<sup>-1</sup>,  $p < 0.0001$ ) in treated tumor-bearing mice from Day 48 to Day 68. When compared with the trend of average nLac in untreated tumor-bearing mice during tumor development, average nLac in treated tumor-bearing mice during tumor recurrence had a nearly identical slope ( $0.0067$  vs.  $0.0069$  days<sup>-1</sup>,  $p = 0.9415$ ). When analyzed with grouped ANOVA analysis, average nLac in treated tumor-bearing mice was significantly increased by Day 68 compared with treated tumor-bearing mice on Days 48 ( $0.44 \pm 0.04$  vs.  $0.31 \pm 0.05$ ,  $p = 0.0085$ ) and 55 ( $0.44 \pm 0.04$  vs.  $0.35 \pm 0.05$ ,  $p = 0.0452$ ) as well as when compared with control mice on Days 28 ( $0.44 \pm 0.04$  vs.  $0.32 \pm 0.10$ ,  $p = 0.0341$ ) and 34 ( $0.44 \pm 0.04$  vs.  $0.22 \pm 0.01$ ,  $p = 0.0002$ ). Furthermore, when analyzing comparisons of individual repeated measurements with mixed-effects analysis, nLac was still significantly increased on Day 68 compared with Day 55 ( $0.44 \pm 0.04$  vs.  $0.35 \pm 0.05$ ,  $p = 0.0214$ ).




**Figure 4.** In vivo pyruvate-to-lactate conversion is significantly altered throughout tumor development, regression, and recurrence. Individual nLac values, measured with hyperpolarized  $^{13}\text{C}$  MRS, are plotted as a function of time for control mice (red circles) and untreated tumor-bearing mice (blue squares) during tumor development (**A**). Individual nLac values are plotted as a function of time for treated tumor-bearing mice (green triangles) during tumor regression and recurrence (**B**). Individual nLac values are plotted as a function of time across the entirety of tumor progression (**C**). Error bars represent standard deviation. Average nLac values between groups and time-points were assessed for significance using ordinary one-way ANOVA and follow-up Fisher's Least Significant Difference tests with significance attributed to comparisons that produced  $p < 0.05$ . \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ .

### 3.4. Ex Vivo Metabolite Pool Sizes Are Significantly Altered throughout Tumor Development and Regression

Tumor Development (Day 1–34): Tumors and controls (healthy murine brain tissue) were excised at the same time-points as the hyperpolarized MRS experiments for ex vivo global metabolomics using NMR spectroscopy. An example spectrum with peaks of metabolites relevant to this study is provided in Figure S1. Pool sizes of 26 metabolites

were quantified and compared between tumors and controls in the same manner as nLac (Figure 5). By Day 28, average pool size of the metabolites alanine ( $3.92 \pm 1.55$  vs.  $1.54 \pm 0.61$   $\mu\text{M}/\text{mg}$ ,  $q = 0.0366$ ) and phosphocholine ( $3.14 \pm 1.62$  vs.  $1.32 \pm 0.49$   $\mu\text{M}/\text{mg}$ ,  $q = 0.0491$ ) were significantly increased in tumors compared with controls. On Day 34, average pool sizes of alanine ( $4.80 \pm 1.98$  vs.  $1.45 \pm 0.97$   $\mu\text{M}/\text{mg}$ ,  $q = 0.0027$ ) and phosphocholine ( $3.40 \pm 1.23$  vs.  $1.17 \pm 0.64$   $\mu\text{M}/\text{mg}$ ,  $q = 0.0144$ ) were still significantly increased in tumors compared with controls along with glycerophosphocholine ( $3.19 \pm 1.14$  vs.  $0.93 \pm 0.34$   $\mu\text{M}/\text{mg}$ ,  $q = 0.0343$ ), glycine ( $10.56 \pm 6.53$  vs.  $2.86 \pm 2.01$   $\mu\text{M}/\text{mg}$ ,  $q = 0.0106$ ), and valine ( $0.81 \pm 0.43$  vs.  $0.28 \pm 0.20$   $\mu\text{M}/\text{mg}$ ,  $q = 0.0072$ ).



**Figure 5.** Ex vivo metabolite pool sizes are significantly altered throughout tumor development and regression. Individual metabolite pool sizes, measured with NMR spectroscopy, are plotted as a function of time for control mice (red circles) and untreated (blue squares) and treated (green triangles) tumor-bearing mice. Error bars represent standard deviation. The Y-axis is reported as concentration of metabolite pool per mg of tissue. Statistical significance was determined using ordinary one-way ANOVA and follow-up Fisher's Least Significant Difference tests. The false discovery rate was controlled using the two-stage step-up method of Benjamini, Krieger and Yekutieli, and significance was attributed to comparisons that produced  $q < 0.05$ . \*  $q < 0.05$ , \*\*  $q < 0.01$ .

Tumor Regression (Day 25–48): Following radiotherapy, samples were excised from treated mice at the same time-points as the hyperpolarized MRS experiments for NMR spectroscopy (Figure 5). On Day 34, average pool size of the following metabolites was significantly decreased in treated tumors compared with untreated tumors: alanine ( $2.20 \pm 1.42$  vs.  $4.80 \pm 1.98$   $\mu\text{M}/\text{mg}$ ,  $q = 0.0072$ ), glycine ( $5.21 \pm 4.23$  vs.  $10.56 \pm 6.53$   $\mu\text{M}/\text{mg}$ ,  $q = 0.0457$ ), and valine ( $0.34 \pm 0.18$  vs.  $0.81 \pm 0.43$   $\mu\text{M}/\text{mg}$ ,  $q = 0.0061$ ). By Day 48, average pool size of these metabolites was still significantly decreased in treated tumors compared with untreated tumors on Day 34 along with the metabolites, NAD<sup>+</sup> ( $0.36 \pm 0.05$  vs.  $0.69 \pm 0.21$   $\mu\text{M}/\text{mg}$ ,  $q = 0.0496$ ) and phosphocholine ( $1.80 \pm 0.79$  vs.  $3.40 \pm 1.23$   $\mu\text{M}/\text{mg}$ ,  $q = 0.0457$ ). Another result of note is that on Day 28, average glutathione pool size was significantly increased in treated tumors compared with treated tumors on Days 41 ( $5.32 \pm 1.79$  vs.  $1.50 \pm 0.58$   $\mu\text{M}/\text{mg}$ ,  $q = 0.0328$ ) and 48 ( $5.32 \pm 1.79$  vs.  $1.81 \pm 0.70$   $\mu\text{M}/\text{mg}$ ,  $q = 0.0491$ ). Refer to Table 1 for all significant metabolite pool size changes throughout tumor development and regression.

**Table 1.** List of significantly altered metabolites during tumor development and/or tumor regression.


Metabolite	Tumor Development	Tumor Regression	Potential Pathway
Valine	U34 > C34, $q = 0.0072$	T34 < U34, $q = 0.0061$ T41 < U34, $q = 0.0013$ T48 < U34, $q = 0.0027$	BCAA Catabolism
Alanine	U28 > C28, $q = 0.0366$ U34 > C34, $q = 0.0027$	T34 < U34, $q = 0.0072$ T41 < U28, $q = 0.0063$ T41 < U34, $q = 0.0004$ T48 < U28, $q = 0.0149$ T48 < U34, $q = 0.0011$	Glutamine Anaplerosis
Glycine	U34 > C34, $q = 0.0106$	T34 < U34, $q = 0.0457$ T41 < U34, $q = 0.0034$ T48 < U34, $q = 0.0021$	Glycine Cleavage, Folate Cycle
Phosphocholine	U28 > C28, $q = 0.0491$ U34 > C34, $q = 0.0144$	T41 < U28, $q = 0.0284$ T41 < U34, $q = 0.0106$ T48 < U34, $q = 0.0457$	Kennedy Pathway, Choline Cycle
Glycero-phosphocholine	U34 > C34, $q = 0.0343$		
Phosphoethanolamine		T41 < U28, $q = 0.0154$ T41 < U34, $q = 0.0496$ T48 < U28, $q = 0.0401$	
Glutathione		T41 > T28, $q = 0.0328$ T48 > T28, $q = 0.0491$	Trans-Sulphuration Pathway
NAD <sup>+</sup>		T41 < U34, $q = 0.0106$ T48 < U34, $q = 0.0496$	Energy Metabolism

In the “Tumor Development” and “Tumor Regression” columns, the naming convention is the group (U = untreated, C = control, T = treated) followed by the time-point. For example, U34 > C34,  $q = 0.0241$  indicates that the metabolite was significantly increased in untreated tumor-bearing mice on Day 34 compared with control mice on Day 34, and the comparison produced a  $q$ -value of 0.0241. The  $q$ -values are  $p$ -values adjusted to control the false discovery rate using the two-stage step-up method of Benjamini, Krieger and Yekutieli. Pathways that the metabolites belong to which have been reported to be upregulated in cancer are also presented.

### 3.5. Ex Vivo MCT1 Expression Significantly Increases throughout Tumor Development

Immunohistochemistry (IHC) was performed on ex vivo tumor samples at several time-points to measure changes in MCT1 and LDH-A expression throughout tumor development (Figure 6). Qualitatively, MCT1 was membrane-bound and LDH-A was confined to the cytoplasm, as expected. Semi-quantitatively, average MCT1 percent stained area was significantly higher in untreated tumors by Day 21 compared with controls ( $13.43 \pm 5.33$  vs.  $3.11 \pm 3.57$ ,  $p = 0.0139$ ;  $13.43 \pm 5.33$  vs.  $2.73 \pm 1.98$ ,  $p = 0.0110$ ) and remained significantly increased through Days 25, 28, and 34. Additionally, average MCT1 percent stained area was significantly higher in untreated tumors by Day 21 compared with untreated tumors

early in development on Day 10, ( $13.43 \pm 5.33$  vs.  $5.15 \pm 4.86$ ,  $p = 0.0459$ ) and remained significantly increased through Days 25, 28, and 34. Conversely, average LDH-A percent stained area was elevated in untreated tumors at all time-points of development, and the only significant increase was on Day 34 when compared with Days 14 ( $37.15 \pm 5.48$  vs.  $19.77 \pm 6.88$ ,  $p = 0.0002$ ), 25 ( $37.15 \pm 5.48$  vs.  $23.86 \pm 5.52$ ,  $p = 0.0030$ ), and 28 ( $37.15 \pm 5.48$  vs.  $20.24 \pm 12.81$ ,  $p = 0.0008$ ).



**Figure 6.** Ex vivo MCT1 expression significantly increases throughout tumor development. Histology stains of H&E, MCT1, and LDH-A were measured in ex vivo untreated tumor samples at several time-points throughout tumor development (A). It can be clearly seen that MCT1 is confined to the cell membrane and LDH-A to the cytoplasm. Percent stained area was calculated from the MCT1 (B) and LHD-A (C) IHC images at these time-points. Average percent stained area between time-points was assessed for significance using ordinary one-way ANOVA and follow-up Fisher's Least Significant Difference tests with significance attributed to comparisons that produced  $p < 0.05$ . \*  $p < 0.05$ , \*\*  $p < 0.01$ .

#### 4. Discussion

Our findings demonstrate that *in situ* analysis of metabolic changes linking the stages of tumor progression (tumor development, regression following radiotherapy, and recurrence) using hyperpolarized MRI and NMR spectroscopy is feasible and informative. By acquiring each of these measurements, along with anatomic growth, in the same mice and at multiple common time-points, the individual evolution of the results from these assays were investigated as well as their relationship and correlation with one another. Thus, an extensive evaluation of cancer metabolism as it advances through different stages of tumor progression was examined. The results from these experiments illustrate that measured pyruvate-to-lactate conversion values are variable in all stages of tumor progression. Therefore, when researchers are using this technique to compare hyperpolarized pyruvate-to-lactate values between tumor types of varying growth rates or before and after treatment, the stage of tumor progression needs to be considered. The mouse model used in this project is an orthotopic implantation of patient-derived GBM (GSC 8-11), which generates confidence that these results are clinically relevant and potentially translatable. However, we do acknowledge the caveat that host immunity is not fully represented in these models.


To our knowledge, this is the first study to investigate all three stages of brain tumor progression, including tumor recurrence, with hyperpolarized MRS. There is one prior study that used hyperpolarized MRSI to measure the glycolytic effects of switching off MYC expression in transgenic mouse models of breast cancer which resulted in tumor regression followed by recurrence [42]. Shin et al. observed that the hyperpolarized lactate:pyruvate ratio significantly decreased as the tumors regressed from MYC withdrawal, and after a latency period, the tumors recurred, which was accompanied by a significant increase of hyperpolarized lactate:pyruvate ratio. In one of the mice, this increase of lactate production was observed prior to increases in tumor volume, which supports the results we observed across multiple treated GBM tumor-bearing mice.

Because average tumor volume values and their variances were low on Day 5, significant increases in untreated tumor volume were detected as soon as Day 10. However, it was not until Day 21 that average tumor volume began to rapidly increase, tripling in value compared with Day 18. Meanwhile, nLac was significantly increased compared with controls beginning on Day 14. Thus, hyperpolarized MRS predicted aggressive growth while the tumor was still in the slow-growing phase. One potential clinical application of this is the ability to distinguish aggressive tumors from their slower-growing counterparts early in tumor development and predict malignant transformation. This would allow physicians to begin administering therapy before the tumor aggressively invades neighboring tissue and is still treatable, which may lead to improvements in patient survival.

Another current clinical challenge facing neuro-oncologists is distinguishing pseudoprogression from true progression following radiotherapy. Pseudoprogression is an anatomic MRI pattern that mimics tumor progression and can confound treatment monitoring with direct consequences in clinical practice. It can lead to prematurely withholding adjuvant temozolomide or continuing with potentially ineffective treatment in patients in which cases of tumor progression are not clear [43]. Pseudoprogression was observed in this study with anatomic MRI as tumor volumes in treated mice significantly increased on Days 34 and 41 before eventually decreasing throughout regression. Conversely, there were no significant increases in nLac during this time-course, which suggests hyperpolarized MR could help mitigate this problem in the clinic.

Furthermore, the predictive value of hyperpolarized MRS to stratify subjects into likely and unlikely responders was alluded to when looking at the initial nLac values following treatment. Of the 10 mice which underwent hyperpolarized MRS immediately following treatment, a cutoff value of nLac > 0.4 was able to predict if a mouse would succumb to tumor burden before the Day 94 endpoint with a sensitivity of 100% and specificity of 60%. These sample sizes are too small to draw definitive conclusions, but it serves as motivation for a larger study.

As the treated tumors proceeded through the regression stage following radiotherapy, nLac decreased significantly in treated tumor-bearing mice on Days 48 and 55 compared with Days 28 and 34, whereas tumor volume did not significantly decrease in this time period. When comparing the quality of the data, there were larger magnitudes of change and lower variance in the hyperpolarized MRS data compared with the anatomic MRI data. This remained true when looking at relative changes of nLac and tumor volume (by normalizing parameters to their initial value following therapy for those mice that were imaged several times throughout regression and recurrence). Within this set of repeated tumor volume measurements, average nLac fell to a minimum of 71% of its initial value after treatment by Day 55 whereas average tumor volume reached a minimum of 81% of its initial treated volume on Day 62 (Figure 7). This suggests that hyperpolarized MRS can effectively detect the response of GBM to radiotherapy and do so more reliably than measuring changes in tumor volume with anatomic MRI.



**Figure 7.** Percent change of nLac, but not tumor volume, is significantly altered during tumor regression and recurrence. Repeated measures of tumor volume are acquired over time in treated mice with anatomic MRI (A) and hyperpolarized MRS (B). At each time-point, volume and nLac were normalized to their initial value following treatment and plotted as percent change over time (C). The data were tested for significance using mixed-effects analysis with the Geisser–Greenhouse correction, and comparisons that produced  $p < 0.05$  were deemed significant. \*  $p < 0.05$ , \*\*\*  $p < 0.001$ .



Hyperpolarized MRS was also effective at detecting early signs of recurrence as nLac was significantly increased in treated mice by Day 68 compared with Days 48 and 55, whereas tumor volume did not significantly increase in this time period. The only significant change in volume that was observed at any time-point following radiotherapy was that average treated tumor volume on Day 72 was significantly increased compared with initial treatment volume on Day 26, which does suggest that the mice were beginning to relapse. Furthermore, nLac values in treated mice on Day 68 were equivalent to initial values following treatment on Days 28 and 34. Thus, there was a complete reversal of nLac behavior by Day 68, further supporting that relapse was occurring. Again, when looking at percent change of nLac and tumor volume in the mice that were measured at multiple time-points throughout regression and recurrence (Figure 7), average nLac significantly increased from its minimum of 71% of its initial value following treatment to 88% by Day 68 ( $p = 0.0258$ ). Average tumor volume increased from its minimum of 81% of its initial value following treatment to 96% by Day 72 ( $p = 0.1084$ ). Based on these data, we suspect that pyruvate-to-lactate conversion measured with hyperpolarized MRS in this animal model is a direct metabolic readout of tumor response during regression (Day 55) and relapse (Day 68) which is occurring prior to radiological tumor volume changes.

Another interesting result is that the slope of nLac in treated tumor-bearing mice in the tumor recurrence stage was nearly identical to that of the untreated tumor-bearing mice in the development stage. This suggests that the metabolic programming of recurring tumors was not altered, and the mechanism of recurrence was similar to that of initial growth. This is expected since tumors were only treated with radiotherapy. Had adjuvant chemotherapy or targeted therapy been implemented, cancer cells could have potentially been pressured to escape therapy through the development of resistance by adapting and reprogramming a new mechanism of survival and proliferation, which may have been reflected in the metabolic assays. This idea is currently of immense interest as metabolic changes that reflect resistance to therapy could be exploited with molecular imaging techniques and would be invaluable to physicians looking to optimize therapeutic approaches. This could have a significant benefit for patients with recurrent disease, and future research will investigate this idea further.

It has been traditionally accepted that an increase of the enzyme lactate dehydrogenase-A (LDH-A) accompanies tumor formation and is the driver of increased pyruvate-to-lactate conversion observed in hyperpolarized MR studies. However, the only significant increase of LDH-A expression as measured with IHC observed in this study was at the final time-point of tumor development on Day 34. Ex vivo lactate pool size in the GSC 8-11 tumors from NMR experiments did not reveal significant changes over the course of tumor progression. Additionally, neither untreated nor treated tumors produced significant correlations between their in vivo nLac values with ex vivo lactate pool sizes, although we have observed this correlation in patient-derived pancreatic cancer mouse models of increasing aggressiveness [44]. While the role of monocarboxylate transporter 1 (MCT1) for transporting pyruvate to the cytosol has been known to be important in hyperpolarized MR exams, it was recently demonstrated that MCT1 may be the key and rate-limiting step for lactate production [45]. Additional studies report correlations of MCT1 with hyperpolarized pyruvate-to-lactate conversion in GBM [23] and breast cancer [46]. Our data seem to support these results as MCT1 significantly increased throughout tumor development and mirrored the trajectory of nLac.

An analysis of the REMBRANDT and TCGA databases of patient brain tumors revealed that *SLC16A1* expression—the gene which encodes MCT1—was elevated in GBM compared with lower-grade astrocytoma, oligodendroma, and non-tumor brain samples [47]. When grouping these glioma subtypes together, those with high expression of *SLC16A1* led to significantly lower survival compared to those with low expression of *SLC16A1* [48]. Further analysis of the TCGA database revealed that MCT1 expression was significantly reduced in IDH1-mutant glioma samples compared to those with wild-type IDH1 [49]. IDH1 mutations are predominately found in WHO grade II and III gliomas

(70% of cases) compared to grade IV GBM (12% of cases), and GBM which harbor the IDH1 mutation lead to significantly longer survival times of greater than two-fold [50,51]. In individual studies, MCT1 immunoreactivity scores were significantly increased in 24 high-grade patient samples of GBM and anaplastic astrocytoma compared with 24 low-grade patient samples of oligodendrogliomas and low-grade astrocytomas [52], and it was significantly increased in 78 GBM patient samples compared with 24 non-tumor brain samples [53]. Furthermore, the MCT inhibitor  $\alpha$ -cyano-4-hydroxycinnamate (CHC) induced cytotoxic effects and inhibited proliferation, invasion, and migration capacity in high-grade glioma cell lines which possessed high expression of MCT1 [53,54]. Because MCT1 has differential expression between malignant and healthy brain cells, and even between low- and high-grade disease, it is an attractive prognostic biomarker. In this study, we have shown that increasing MCT1 expression correlates with hyperpolarized pyruvate-to-lactate conversion throughout GBM tumor development. In patients with prostate [55] and breast cancers [46], similar correlations of MCT1 expression and hyperpolarized pyruvate-to-lactate conversion were observed which also correlated with tumor grade. Thus, hyperpolarized MRS has a promising clinical application in the early detection of high-grade brain cancer through MCT1 interrogation.

In addition to probing changes in glycolytic metabolism, we were also interested in identifying alternate metabolic pathways which were potentially deregulated throughout tumor progression. These could serve as leads for subsequent imaging probes and therapeutic targets. Results from the NMR experiments of the *ex vivo* tissue samples demonstrated that amino acid metabolism was significantly altered throughout tumor progression. These metabolites are essential for protein synthesis and are necessary for cellular growth and division. In particular, the pool sizes of valine, alanine, and glycine were significantly increased by the end of tumor development and decreased following radiotherapy. Valine is a branched chain amino acid (BCAA) and can be used for protein synthesis or oxidized for energy production. Branched-chain aminotransferase 1 (BCAT1) generates glutamate during BCAA catabolism and is overexpressed in many cancers including glioma [56–59]. Alanine and  $\alpha$ -ketoglutarate can be reversibly produced from pyruvate and glutamate through alanine transaminase (ALT) whenever the pyruvate substrate is available. In some hyperpolarized [ $^{13}\text{C}$ ]pyruvate MR experiments, it is possible to observe hyperpolarized alanine production, and a decreasing ratio of hyperpolarized alanine-to-lactate has been suggested as a biomarker of disease progression in pancreatic cancer [60,61]. Unfortunately, we could not reliably observe hyperpolarized alanine in our experiments to suggest the same is true for GBM. Increased glutamine anaplerosis via ALT has been linked to the viability and proliferation of brain [62], breast [63,64], colorectal [65], and prostate [66] cancers. It was recently demonstrated that alanine uptake and utilization through the SLC38A2 membrane transporter played a key role in pancreatic cancer metabolism and proliferation [67]. Glycine is derived from serine in one-carbon metabolism to maintain redox balance through antioxidant production such as glutathione as well as to produce metabolites involved in purine nucleotide and lipid synthesis, all of which are important for cancer survival and proliferation [68]. Glycine production through serine hydroxymethyltransferase (SHMT)—a transcriptional target of c-Myc [69]—has been implicated as a driver of cancer cell proliferation in glioma [70] and many other types of tumors [71–75].

Many tumors rely on antioxidants to quench the effects of reactive oxygen species (ROS) produced from treatments such as radiotherapy and chemotherapy [76] as well as oxidative stress from increased energy metabolism [77]. This is often seen through an increased production of NADPH and glutathione through the pentose phosphate pathway and one-carbon metabolism [78]. We observed a significant increase in *ex vivo* glutathione pool size in treated tumors one day following radiotherapy compared with treated tumors further into regression, which we believe is an acute response to increased ROS generated from radiotherapy. Increased concentration of antioxidants such as glutathione in tumors immediately following treatment has also been reported elsewhere [79,80].

Increased phospholipid metabolism was observed in these GBM tumors compared with normal brain tissue and correlated with progression. The Kennedy pathway describes the phosphorylation of choline and ethanolamine to phosphocholine and phosphoethanolamine, which eventually form phosphatidylcholine and phosphatidylethanolamine [81]. These are the two most abundant phospholipids in the cell membrane. The second messenger diacylglycerol is produced in this pathway which can further activate downstream signaling for cellular growth and fatty acid oxidation [82]. Phosphatidylcholine can be broken down into glycerophosphocholine for storage and eventually converted back into choline. Increased phosphocholine and choline-containing metabolite concentrations have been observed in gliomas [62,83–86] and many other types of cancer [87–89], so it was not surprising to see significantly elevated pools of these metabolites, along with phosphoethanolamine in untreated tumors compared with controls and treated tumors.

Nicotinamide adenine dinucleotide (NAD<sup>+</sup>) is an important cofactor in cellular metabolism and is necessary for glycolysis, pyruvate-to-lactate conversion, and serine biosynthesis. Nicotinamide phosphoribosyltransferase (NAMPT) is the main enzyme for NAD<sup>+</sup> biosynthesis and has been found to be upregulated in several cancers including glioma [90,91]. Inhibition of this enzyme leads to antitumoral effects, which has led to the development of drugs for different types of cancer [92–96]. We observed a significant decrease in NAD<sup>+</sup> levels following treatment.

A potential weakness of this study lies in the fact that the hyperpolarized <sup>13</sup>C MRS experiments were performed using slab-localized spectroscopy, rather than spectroscopic imaging. In other words, the average pyruvate-to-lactate conversion was localized to a volumetric region of interest, rather than imaged across multiple voxels. Both methods of measuring *in vivo* pyruvate-to-lactate conversion are accepted in the literature, but as advances in coil engineering and sequence design (which would allow for detectable <sup>13</sup>C SNR in mm-sized voxels) becomes more standard, the field will likely favor spectroscopic imaging of hyperpolarized pyruvate and lactate exclusively [97]. By imaging pyruvate-to-lactate conversion (often visualized as  $k_{PL}$  parameter maps), both aggressive subregional areas of the tumor as well microscopic extensions of the anatomically visible tumor can be identified [98]. This could facilitate alternative treatment strategies such as dose painting to irradiate aggressive subregions to higher doses, which should result in improved tumor control. Additionally, non-uniformly expanding gross tumor volume margins to only include areas with evidence of microscopic disease, rather than uniformly expanding the gross tumor volume by an arbitrary distance to include suspected microscopic disease, could lead to the reduction of radiation-induced side effects by limiting the amount of healthy tissue in high-dose regions. Ultimately, clinical implementation of hyperpolarized MR will likely take the form of spectroscopic imaging, rather than slab-localized spectroscopy [6]. Regardless, the results from this study are still relevant to the field as metabolic transformations from the tumor as a whole could still be detected, which suggests that this technique would bring great value to the care of glioblastoma patients in each of the ways mentioned in this manuscript.

In addition to uncovering potential diagnostic and therapeutic targets of metabolism, the data from this analysis can be combined with *in vivo* hyperpolarized MR data to build a model based on tumor metabolism to predict clinical outcomes. Correlative analysis demonstrated that hyperpolarized MR and NMR spectroscopy data are largely orthogonal (with hyperpolarized MR measuring real-time flux and NMR spectroscopy measuring metabolite pool size), so this model should be more predictive than either technique alone. Unfortunately, we could not implement this in our study because the tumor excision process for NMR spectroscopy requires euthanasia of the mice, preventing validation of treatment response or survival outcomes. However, in the clinical setting, biopsies of tumor tissue can be obtained during diagnosis as well as post-surgery, which could then be processed for NMR spectroscopy. Combining these data with hyperpolarized MR acquisitions at these time-points to predict clinical outcomes could form the basis for a clinical trial.

## 5. Conclusions

This study demonstrated and discussed the benefits that hyperpolarized MRS could add to conventional clinical imaging to address several clinical challenges in the diagnosis and treatment of GBM. These include the ability to predict whether a tumor will be slow-growing or aggressive at the time of diagnosis, help discriminate pseudoprogression from true progression and predict whether patient survival will be improved shortly after administration of a treatment, and determine whether the patient is on the verge of relapse during a follow-up exam. Each of these scenarios would give physicians the time to take appropriate interventional action, improving the chances of patient survival.

In vivo metabolic measurements with hyperpolarized MRS were supported by ex vivo global metabolomics with NMR spectroscopy and protein expression assays with IHC to provide a comprehensive analysis of tumor metabolism. A major innovation in this study is that these measurements of metabolism, along with tumor volume, were made at several time-points across tumor development, regression, and recurrence. Thus, the individual evolution of tumor volume, hyperpolarized pyruvate-to-lactate conversion, and ex vivo metabolite pool sizes could be studied as well as their correlations with each other over time. As hyperpolarized MR makes its way through clinical trials as a metabolic imaging modality, we believe its value in cancer care will continue to grow. Just as positron emission tomography (PET) became a staple in the clinic, so too should hyperpolarized MRI as an invaluable tool for interrogating the metabolism of cancer.

**Supplementary Materials:** The following are available online at <https://www.mdpi.com/article/10.3390/cells10102621/s1>, Figure S1: Representative NMR spectrum for ex vivo metabolomic analysis.

**Author Contributions:** Conceptualization, T.C.S., F.F.L. and P.K.B.; methodology, T.C.S., V.M., J.W., A.S. and J.G.; software, T.C.S.; validation, T.C.S. and P.K.B.; formal analysis, T.C.S., V.M. and A.S.; investigation, T.C.S., N.M.Z. and S.T.G.; resources, N.M.Z., S.T.G., D.P.-W. and G.N.F.; data curation, T.C.S.; writing—original draft preparation, T.C.S. and P.K.B.; writing—review and editing, J.W., N.M.Z., S.T.G., D.P.-W. and C.J.L.; visualization, T.C.S., G.N.F. and P.K.B.; supervision, C.J.L., F.F.L. and P.K.B.; project administration, P.K.B.; funding acquisition, T.C.S. and P.K.B. All authors have read and agreed to the published version of the manuscript.

**Funding:** The research has been funded in part by MD Anderson Institutional Research Grants, MD Anderson Institutional Startup, Brain SPORE Developmental Research Award (NCI P50CA127001), and Koch Foundation. We also thank the CCSG-funded NMR facility core facility and small animal imaging facility (SAIF) (CA016672). T.C.S. acknowledges CPRIT Research Training Award (RP170067) for graduate stipend support.

**Institutional Review Board Statement:** All procedures were performed in accordance with regulations of the Institutional Animal Care and Use Committee (00001263-RN02; 00001008-RN01) and Institutional Review Board (LAB04-0001) of the University of Texas MD Anderson Cancer Center.

**Informed Consent Statement:** Each patient in this study provided written informed consent for tumor tissues collection.

**Data Availability Statement:** The dataset containing all tumor volume, nLac, metabolite pool size, and protein expression values generated during this study as well as the MATLAB code used to calculate nLac from raw hyperpolarized  $^{13}\text{C}$  spectral data are available at <http://dx.doi.org/10.17632/mf5f93t3kn.1>.

**Acknowledgments:** We gratefully acknowledge Jorge Delacerda, Charles Kingsley, James Bankson, and John Hazle for support with animal imaging. TCS also acknowledges Richard Wendt and Ho-Ling Anthony Liu for graduate advisory support. TCS further acknowledges Prasanta Dutta, Shivanand Pudukalakatti, and Jaehyuk Lee for experimental training.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Ostrom, Q.T.; Cioffi, G.; Gittleman, H.; Patil, N.; Waite, K.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. *Neuro-Oncol.* **2019**, *21*, v1–v100. [\[CrossRef\]](#)
2. Stupp, R.; Hegi, M.E.; Mason, W.P.; van den Bent, M.J.; Taphoorn, M.J.B.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.; Fisher, B.; Belanger, K.; et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol.* **2009**, *10*, 459–466. [\[CrossRef\]](#)
3. Hodges, T.R.; Ott, M.; Xiu, J.; Gatalica, Z.; Swensen, J.; Zhou, S.; Huse, J.T.; De Groot, J.; Li, S.; Overwijk, W.W.; et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: Implications for immune checkpoint immunotherapy. *Neuro Oncol.* **2017**, *19*, 1047–1057. [\[CrossRef\]](#) [\[PubMed\]](#)
4. Salzillo, T.; Hu, J.; Nguyen, L.; Whiting, N.; Lee, J.; Weygand, J.; Dutta, P.; Pudakalakatti, S.; Millward, N.Z.; Gammon, S.; et al. Interrogating Metabolism in Brain Cancer. *Magn. Reson. Imaging Clin. N. Am.* **2016**, *24*, 687–703. [\[CrossRef\]](#) [\[PubMed\]](#)
5. Hu, J.; Salzillo, T.; Sailasuta, N.; Lang, F.F.; Bhattacharya, P. Interrogating IDH Mutation in Brain Tumor. *Top. Magn. Reson. Imaging* **2017**, *26*, 27–32. [\[CrossRef\]](#)
6. Kurhanewicz, J.; Vigneron, D.B.; Ardenkjaer-Larsen, J.H.; Bankson, J.A.; Brindle, K.; Cunningham, C.; Gallagher, F.A.; Keshari, K.R.; Kjaer, A.; Laustsen, C.; et al. Hyperpolarized <sup>13</sup>C MRI: Path to Clinical Translation in Oncology. *Neoplasia* **2019**, *21*, 1–16. [\[CrossRef\]](#) [\[PubMed\]](#)
7. Dutta, P.; Salzillo, T.C.; Pudakalakatti, S.; Gammon, S.T.; Kaiparettu, B.A.; McAllister, F.; Wagner, S.; Frigo, D.E.; Logothetis, C.J.; Zacharias, N.M.; et al. Assessing Therapeutic Efficacy in Real-time by Hyperpolarized Magnetic Resonance Metabolic Imaging. *Cells* **2019**, *8*, 340. [\[CrossRef\]](#)
8. Brindle, K. Watching tumours gasp and die with MRI: The promise of hyperpolarised <sup>13</sup>C MR spectroscopic imaging. *Br. J. Radiol.* **2012**, *85*, 697–708. [\[CrossRef\]](#) [\[PubMed\]](#)
9. Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. *Science* **2009**, *324*, 1029–1033. [\[CrossRef\]](#)
10. Warburg, O. On the Origin of Cancer Cells. *Science* **1956**, *123*, 309–314. [\[CrossRef\]](#)
11. Lee, C.Y.; Soliman, H.; Geraghty, B.J.; Chen, A.P.; Connelly, K.A.; Endre, R.; Perks, W.J.; Heyn, C.; Black, S.E.; Cunningham, C.H. Lactate topography of the human brain using hyperpolarized <sup>13</sup>C-MRI. *NeuroImage* **2020**, *204*, 116202. [\[CrossRef\]](#) [\[PubMed\]](#)
12. Grist, J.; McLean, M.A.; Riemer, F.; Schulte, R.F.; Deen, S.S.; Zaccagna, F.; Woitek, R.; Daniels, C.J.; Kaggie, J.; Matys, T.; et al. Quantifying normal human brain metabolism using hyperpolarized [1-<sup>13</sup>C]pyruvate and magnetic resonance imaging. *NeuroImage* **2019**, *189*, 171–179. [\[CrossRef\]](#)
13. Chung, B.T.; Chen, H.-Y.; Gordon, J.; Mammoli, D.; Sriram, R.; Autry, A.W.; Le Page, L.M.; Chaumeil, M.; Shin, P.; Slater, J.; et al. First hyperpolarized [2-<sup>13</sup>C]pyruvate MR studies of human brain metabolism. *J. Magn. Reson.* **2019**, *309*, 106617. [\[CrossRef\]](#) [\[PubMed\]](#)
14. Miloushev, V.Z.; Granlund, K.L.; Boltyskiy, R.; Lyashchenko, S.K.; DeAngelis, L.M.; Mellinghoff, I.K.; Brennan, C.; Tabar, V.; Yang, T.J.; Holodny, A.; et al. Metabolic Imaging of the Human Brain with Hyperpolarized <sup>13</sup>C Pyruvate Demonstrates <sup>13</sup>C Lactate Production in Brain Tumor Patients. *Cancer Res.* **2018**, *78*, 3755–3760. [\[CrossRef\]](#)
15. Gordon, J.W.; Chen, H.-Y.; Autry, A.; Park, I.; Van Criekinge, M.; Mammoli, D.; Milshteyn, E.; Bok, R.; Xu, D.; Li, Y.; et al. Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients. *Magn. Reson. Med.* **2019**, *81*, 2702–2709. [\[CrossRef\]](#)
16. Park, I.; Larson, P.E.; Gordon, J.W.; Carvajal, L.; Chen, H.-Y.; Bok, R.; Van Criekinge, M.; Ferrone, M.; Slater, J.B.; Xu, D.; et al. Development of methods and feasibility of using hyperpolarized carbon-13 imaging data for evaluating brain metabolism in patient studies. *Magn. Reson. Med.* **2018**, *80*, 864–873. [\[CrossRef\]](#)
17. Mammoli, D.; Gordon, J.; Autry, A.; Larson, P.E.Z.; Li, Y.; Chen, H.-Y.; Chung, B.; Shin, P.; Van Criekinge, M.; Carvajal, L.; et al. Kinetic Modeling of Hyperpolarized Carbon-13 Pyruvate Metabolism in the Human Brain. *IEEE Trans. Med Imaging* **2020**, *39*, 320–327. [\[CrossRef\]](#) [\[PubMed\]](#)
18. Crane, J.C.; Gordon, J.W.; Chen, H.; Autry, A.W.; Li, Y.; Olson, M.P.; Kurhanewicz, J.; Vigneron, D.B.; Larson, P.E.; Xu, D. Hyperpolarized <sup>13</sup>C MRI data acquisition and analysis in prostate and brain at University of California, San Francisco. *NMR Biomed.* **2021**, *34*, e4280. [\[CrossRef\]](#)
19. Chaumeil, M.M.; Radoul, M.; Najac, C.; Eriksson, P.; Viswanath, P.; Blough, M.D.; Chesnelong, C.; Luchman, H.A.; Cairncross, J.G.; Ronen, S.M. Hyperpolarized <sup>13</sup>C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring. *NeuroImage: Clin.* **2016**, *12*, 180–189. [\[CrossRef\]](#) [\[PubMed\]](#)
20. Park, J.M.; Josan, S.; Jang, T.; Merchant, M.; Yen, Y.-F.; Hurd, R.E.; Recht, L.; Spielman, D.M.; Mayer, D. Metabolite kinetics in C6 rat glioma model using magnetic resonance spectroscopic imaging of hyperpolarized [1-<sup>13</sup>C]pyruvate. *Magn. Reson. Med.* **2012**, *68*, 1886–1893. [\[CrossRef\]](#)
21. Park, J.M.; Josan, S.; Jang, T.; Merchant, M.; Watkins, R.; Hurd, R.E.; Recht, L.D.; Mayer, D.; Spielman, D.M. Volumetric spiral chemical shift imaging of hyperpolarized [2-<sup>13</sup>C]pyruvate in a rat c6 glioma model. *Magn. Reson. Med.* **2016**, *75*, 973–984. [\[CrossRef\]](#) [\[PubMed\]](#)

22. Autry, A.W.; Hashizume, R.; James, C.D.; Larson, P.E.Z.; Vigneron, D.B.; Park, I. Measuring Tumor Metabolism in Pediatric Diffuse Intrinsic Pontine Glioma Using Hyperpolarized Carbon-13 MR Metabolic Imaging. *Contrast Media Mol. Imaging* **2018**, *2018*, 1–6. [[CrossRef](#)]
23. Mair, R.; Wright, A.J.; Ros, S.; Hu, D.-E.; Booth, T.; Kreis, F.; Rao, J.; Watts, C.; Brindle, K.M.; Booth, T.C. Metabolic Imaging Detects Low Levels of Glycolytic Activity That Vary with Levels of c-Myc Expression in Patient-Derived Xenograft Models of Glioblastoma. *Cancer Res.* **2018**, *78*, 5408–5418. [[CrossRef](#)] [[PubMed](#)]
24. Day, S.E.; Kettunen, M.; Cherukuri, M.K.; Mitchell, J.B.; Lizak, M.J.; Morris, H.D.; Matsumoto, S.; Koretsky, A.; Brindle, K.M. Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1-13 C]pyruvate and 13 C magnetic resonance spectroscopic imaging. *Magn. Reson. Med.* **2011**, *65*, 557–563. [[CrossRef](#)] [[PubMed](#)]
25. Park, I.; Bok, R.; Ozawa, T.; Phillips, J.J.; James, C.D.; Vigneron, D.B.; Ronen, S.M.; Nelson, S.J. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. *J. Magn. Reson. Imaging* **2011**, *33*, 1284–1290. [[CrossRef](#)]
26. Datta, K.; Lauritzen, M.H.; Merchant, M.; Jang, T.; Liu, S.-C.; Hurd, R.; Recht, L.; Spielman, D.M. Reversed metabolic reprogramming as a measure of cancer treatment efficacy in rat C6 glioma model. *PLoS ONE* **2019**, *14*, e0225313. [[CrossRef](#)]
27. Michel, K.A.; Zieliński, R.; Walker, C.M.; Le Roux, L.; Priebe, W.; Bankson, J.A.; Schellingerhout, D. Hyperpolarized Pyruvate MR Spectroscopy Depicts Glycolytic Inhibition in a Mouse Model of Glioma. *Radiol.* **2019**, *293*, 168–173. [[CrossRef](#)]
28. Seyfried, T.N.; Kiebish, M.A.; Marsh, J.; Shelton, L.M.; Huysentruyt, L.C.; Mukherjee, P. Metabolic management of brain cancer. *Biochim. Biophys. Acta (BBA)—Bioenerg.* **2011**, *1807*, 577–594. [[CrossRef](#)]
29. Libby, C.; Tran, A.; Scott, S.E.; Griguer, C.; Hjelmeland, A.B. The pro-tumorigenic effects of metabolic alterations in glioblastoma including brain tumor initiating cells. *Biochim. Biophys. Acta (BBA)—Bioenerg.* **2018**, *1869*, 175–188. [[CrossRef](#)]
30. Robertson-Tessi, M.; Gillies, R.J.; Gatenby, R.A.; Anderson, A. Impact of Metabolic Heterogeneity on Tumor Growth, Invasion, and Treatment Outcomes. *Cancer Res.* **2015**, *75*, 1567–1579. [[CrossRef](#)]
31. Van Linde, M.E.; Brahm, C.G.; Hamer, P.D.W.; Reijneveld, J.C.; Bruynzeel, A.M.E.; Vandertop, W.P.; Van De Ven, P.M.; Wagemakers, M.; Van Der Weide, H.L.; Enting, R.H.; et al. Treatment outcome of patients with recurrent glioblastoma multiforme: A retrospective multicenter analysis. *J. Neuro-Oncol.* **2017**, *135*, 183–192. [[CrossRef](#)]
32. Zhao, Y.-H.; Wang, Z.-F.; Pan, Z.-Y.; Péus, D.; Fernandez, J.D.; Pallud, J.; Li, Z.-Q. A Meta-Analysis of Survival Outcomes Following Reoperation in Recurrent Glioblastoma: Time to Consider the Timing of Reoperation. *Front. Neurol.* **2019**, *10*, 286. [[CrossRef](#)]
33. Mansouri, S.; Singh, S.; Alamsahebpour, A.; Burrell, K.; Li, M.; Karabork, M.; Ekinici, C.; Koch, E.; Solaroglu, I.; Chang, J.T.; et al. DICER governs characteristics of glioma stem cells and the resulting tumors in xenograft mouse models of glioblastoma. *Oncotarget* **2016**, *7*, 56431–56446. [[CrossRef](#)] [[PubMed](#)]
34. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T.; Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. *Nature* **2004**, *432*, 396–401. [[CrossRef](#)] [[PubMed](#)]
35. Wei, J.; Barr, J.; Kong, L.-Y.; Wang, Y.; Wu, A.; Sharma, A.K.; Gumin, J.; Henry, V.; Colman, H.; Priebe, W.; et al. Glioblastoma Cancer-Initiating Cells Inhibit T-Cell Proliferation and Effector Responses by the Signal Transducers and Activators of Transcription 3 Pathway. *Mol. Cancer Ther.* **2010**, *9*, 67–78. [[CrossRef](#)]
36. Lal, S.; Lacroix, M.; Tofilon, P.; Fuller, G.; Sawaya, R.; Lang, F.F. An implantable guide-screw system for brain tumor studies in small animals. *J. Neurosurg.* **2000**, *92*, 326–333. [[CrossRef](#)]
37. Fedorov, A.; Beichel, R.; Kalpathy-Cramer, J.; Finet, J.; Fillion-Robin, J.-C.; Pujol, S.; Bauer, C.; Jennings, D.; Fennessy, F.; Sonka, M.; et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. *Magn. Reson. Imaging* **2012**, *30*, 1323–1341. [[CrossRef](#)]
38. Weygand, J.; Carter, S.E.; Salzillo, T.C.; Moussalli, M.; Dai, B.; Dutta, P.; Zuo, X.; Fleming, J.B.; Shureiqi, I.; Bhattacharya, P. Can an Organoid Recapitulate the Metabolome of its Parent Tissue? A Pilot NMR Spectroscopy Study. *J. Cancer Prev. Curr. Res.* **2017**, *8*, 1–6. [[CrossRef](#)]
39. Zacharias, N.M.; McCullough, C.; Shanmugavelandy, S.; Lee, J.; Lee, Y.; Dutta, P.; McHenry, J.; Nguyen, L.; Norton, W.; Jones, L.W.; et al. Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer. *Sci. Rep.* **2017**, *7*, 1–11. [[CrossRef](#)]
40. Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, C.; Saalfeld, S.; Schmid, B.; et al. Fiji: An open-source platform for biological-image analysis. *Nat. Methods* **2012**, *9*, 676–682. [[CrossRef](#)] [[PubMed](#)]
41. Ruifrok, A.C.; Johnston, D.A. Quantification of histochemical staining by color deconvolution. *Anal. Quant. Cytol. Histol.* **2001**, *23*, 291–299.
42. Shin, P.J.; Zhu, Z.; Camarda, R.; Bok, R.A.; Zhou, A.; Kurhanewicz, J.; Goga, A.; Vigneron, D.B. Cancer recurrence monitoring using hyperpolarized [1-13C]pyruvate metabolic imaging in murine breast cancer model. *Magn. Reson. Imaging* **2017**, *43*, 105–109. [[CrossRef](#)]
43. Taal, W.; Brandsma, D.; De Bruin, H.G.; Bromberg, J.E.C.; Swaak-Kragten, A.T.; Smitt, P.A.E.S.; Van Es, C.A.; Van Den Bent, M. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoradiation with temozolomide. *Cancer* **2008**, *113*, 405–410. [[CrossRef](#)] [[PubMed](#)]

44. Dutta, P.; Perez, M.R.; Lee, J.; Kang, Y.; Pratt, M.; Salzillo, T.; Weygand, J.; Zacharias, N.M.; Gammon, S.; Koay, E.J.; et al. Combining Hyperpolarized Real-Time Metabolic Imaging and NMR Spectroscopy To Identify Metabolic Biomarkers in Pancreatic Cancer. *J. Proteome Res.* **2019**, *18*, 2826–2834. [[CrossRef](#)]
45. Rao, Y.; Gammon, S.; Zacharias, N.M.; Liu, T.; Salzillo, T.; Xi, Y.; Wang, J.; Bhattacharya, P.; Piwnica-Worms, D. Hyperpolarized [1-13C]pyruvate-to-[1-13C]lactate conversion is rate-limited by monocarboxylate transporter-1 in the plasma membrane. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 22378–22389. [[CrossRef](#)] [[PubMed](#)]
46. Gallagher, F.A.; Woitek, R.; McLean, M.A.; Gill, A.B.; Garcia, R.M.; Provenzano, E.; Riemer, F.; Kaggie, J.; Chhabra, A.; Ursprung, S.; et al. Imaging breast cancer using hyperpolarized carbon-13 MRI. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 2092–2098. [[CrossRef](#)]
47. Ghosh, D.; Ulasov, I.; Chen, L.; Harkins, L.E.; Wallenborg, K.; Hothi, P.; Rostad, S.; Hood, L.; Cobbs, C.S. TGF $\beta$ -Responsive HMOX1 Expression Is Associated with Stemness and Invasion in Glioblastoma Multiforme. *Stem Cells* **2016**, *34*, 2276–2289. [[CrossRef](#)]
48. Park, S.J.; Smith, C.P.; Wilbur, R.R.; Cain, C.P.; Kallu, S.R.; Valasapalli, S.; Sahoo, A.; Guda, M.R.; Tsung, A.J.; Velpula, K.K. An overview of MCT1 and MCT4 in GBM: Small molecule transporters with large implications. *Am. J. Cancer Res.* **2018**, *8*, 1967–1976.
49. Viswanath, P.; Najac, C.; Izquierdo-Garcia, J.; Pankov, A.; Hong, C.; Eriksson, P.; Costello, J.F.; Pieper, R.O.; Ronen, S.M. Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. *Oncotarget* **2016**, *7*, 34942–34955. [[CrossRef](#)] [[PubMed](#)]
50. Yan, H.; Parsons, D.W.; Jin, G.; McLendon, R.; Rasheed, B.A.; Yuan, W.; Kos, I.; Batinic-Haberle, I.; Jones, S.; Riggins, G.J.; et al. IDH1 and IDH2 Mutations in Gliomas. *N. Engl. J. Med.* **2009**, *360*, 765–773. [[CrossRef](#)]
51. Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.-H.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.-M.; Gallia, G.L.; et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme. *Science* **2008**, *321*, 1807–1812. [[CrossRef](#)]
52. Froberg, M.K.; Gerhart, D.Z.; Enerson, B.E.; Manivel, C.; Guzman-Paz, M.; Seacotte, N.; Drewes, L.R. Expression of monocarboxylate transporter MCT1 in normal and neoplastic human CNS tissues. *NeuroReport* **2001**, *12*, 761–765. [[CrossRef](#)] [[PubMed](#)]
53. Miranda-Gonçalves, V.; Honavar, M.; Pinheiro, C.; Martinho, O.; Pires, M.; Pinheiro, C.; Cordeiro, M.; Bebiano, G.; Costa, P.; Palmeirim, I.; et al. Monocarboxylate transporters (MCTs) in gliomas: Expression and exploitation as therapeutic targets. *Neuro-Oncol.* **2012**, *15*, 172–188. [[CrossRef](#)] [[PubMed](#)]
54. Colen, C.B.; Shen, Y.; Ghoddoussi, F.; Yu, P.; Francis, T.B.; Koch, B.J.; Monterey, M.D.; Galloway, M.; Sloan, A.E.; Mathupala, S.P. Metabolic Targeting of Lactate Efflux by Malignant Glioma Inhibits Invasiveness and Induces Necrosis: An In Vivo Study. *Neoplasia* **2011**, *13*, 620–632. [[CrossRef](#)]
55. Granlund, K.L.; Tee, S.-S.; Vargas, H.A.; Lyashchenko, S.K.; Reznik, E.; Fine, S.; Laudone, V.; Eastham, J.A.; Touijer, K.A.; Reuter, V.E.; et al. Hyperpolarized MRI of Human Prostate Cancer Reveals Increased Lactate with Tumor Grade Driven by Monocarboxylate Transporter 1. *Cell Metab.* **2020**, *31*, 105–114.e3. [[CrossRef](#)] [[PubMed](#)]
56. Bianchi, L.; De Micheli, E.; Bricolo, A.; Ballini, C.; Fattori, M.; Venturi, C.; Pedata, F.; Tipton, K.F.; Della Corte, L. Extracellular Levels of Amino Acids and Choline in Human High Grade Gliomas: An Intraoperative Microdialysis Study. *Neurochem. Res.* **2004**, *29*, 325–334. [[CrossRef](#)] [[PubMed](#)]
57. Ananieva, E.A.; Wilkinson, A.C. Branched-chain amino acid metabolism in cancer. *Curr. Opin. Clin. Nutr. Metab. Care* **2018**, *21*, 64–70. [[CrossRef](#)]
58. Tönjes, M.; Barbus, S.; Park, Y.J.; Wang, W.; Schlotter, M.; Lindroth, A.M.; Pleier, S.V.; Bai, A.H.C.; Karra, D.; Piro, R.M.; et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. *Nat. Med.* **2013**, *19*, 901–908. [[CrossRef](#)]
59. Suh, E.H.; Hackett, E.P.; Wynn, R.M.; Chuang, D.T.; Zhang, B.; Luo, W.; Sherry, A.D.; Park, J.M. In vivo assessment of increased oxidation of branched-chain amino acids in glioblastoma. *Sci. Rep.* **2019**, *9*, 340. [[CrossRef](#)]
60. Serrao, E.M.; Kettunen, M.I.; Rodrigues, T.B.; Dzien, P.; Wright, A.J.; Gopinathan, A.; Gallagher, F.A.; Lewis, D.Y.; Frese, K.K.; Almeida, J.; et al. MRI with hyperpolarised [1-13C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model. *Gut* **2015**, *65*, 465–475. [[CrossRef](#)]
61. Dutta, P.; Pando, S.C.; Mascaro, M.; Riquelme, E.; Zoltan, M.; Zacharias, N.M.; Gammon, S.T.; Piwnica-Worms, D.; Pagel, M.D.; Sen, S.; et al. Early Detection of Pancreatic Intraepithelial Neoplasias (PanINs) in Transgenic Mouse Model by Hyperpolarized 13C Metabolic Magnetic Resonance Spectroscopy. *Int. J. Mol. Sci.* **2020**, *21*, 3722. [[CrossRef](#)]
62. Jalbert, L.E.; Elkhaled, A.; Phillips, J.J.; Neill, E.; Williams, A.; Crane, J.C.; Olson, M.P.; Molinaro, A.M.; Berger, M.S.; Kurhanewicz, J.; et al. Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma. *Sci. Rep.* **2017**, *7*, 44792. [[CrossRef](#)]
63. Coloff, J.L.; Murphy, J.P.; Braun, C.R.; Harris, I.; Shelton, L.M.; Kami, K.; Gygi, S.P.; Selfors, L.M.; Brugge, J.S. Differential Glutamate Metabolism in Proliferating and Quiescent Mammary Epithelial Cells. *Cell Metab.* **2016**, *23*, 867–880. [[CrossRef](#)] [[PubMed](#)]
64. Cao, Y.; Lin, S.-H.; Wang, Y.; Chin, Y.E.; Kang, L.; Mi, J. Glutamic Pyruvate Transaminase GPT2 Promotes Tumorigenesis of Breast Cancer Cells by Activating Sonic Hedgehog Signaling. *Theranostics* **2017**, *7*, 3021–3033. [[CrossRef](#)]
65. Hao, Y.; Samuels, Y.; Li, Q.; Krokowski, D.; Guan, B.-J.; Wang, C.; Jin, Z.; Dong, B.; Cao, B.; Feng, X.; et al. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. *Nat. Commun.* **2016**, *7*, 11971. [[CrossRef](#)] [[PubMed](#)]
66. Itkonen, H.M.; Gorad, S.S.; Duveau, D.Y.; Martin, S.; Barkovskaya, A.; Bathen, T.F.; Moestue, S.A.; Mills, I.G. Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism. *Oncotarget* **2016**, *7*, 12464–12476. [[CrossRef](#)]

67. Parker, S.; Amendola, C.R.; Hollinshead, K.E.R.; Yu, Q.; Yamamoto, K.; Encarnación-Rosado, J.; Rose, R.E.; LaRue, M.M.; Sohn, A.S.W.; Biancur, D.E.; et al. Selective Alanine Transporter Utilization Creates a Targetable Metabolic Niche in Pancreatic Cancer. *Cancer Discov.* **2020**, *10*, 1018–1037. [[CrossRef](#)]
68. Ducker, G.S.; Rabinowitz, J.D. One-Carbon Metabolism in Health and Disease. *Cell Metab.* **2017**, *25*, 27–42. [[CrossRef](#)]
69. Nikiforov, M.A.; Chandriani, S.; O’Connell, B.; Petrenko, O.; Kotenko, I.; Beavis, A.; Sedivy, J.M.; Cole, M.D. A Functional Screen for Myc-Responsive Genes Reveals Serine Hydroxymethyltransferase, a Major Source of the One-Carbon Unit for Cell Metabolism. *Mol. Cell. Biol.* **2002**, *22*, 5793–5800. [[CrossRef](#)] [[PubMed](#)]
70. Tiwari, V.; Daoud, E.; Hatanpaa, K.J.; Gao, A.; Zhang, S.; An, Z.; Ganji, S.K.; Raisanen, J.M.; Lewis, C.M.; Askari, P.; et al. Glycine by MR spectroscopy is an imaging biomarker of glioma aggressiveness. *Neuro-Oncol.* **2020**, *22*, 1018–1029. [[CrossRef](#)]
71. Zhang, W.C.; Shyh-Chang, N.; Yang, H.; Rai, A.; Umashankar, S.; Ma, S.; Soh, B.S.; Sun, L.L.; Tai, B.C.; Nga, M.E.; et al. Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and Tumorigenesis. *Cell* **2012**, *148*, 259–272. [[CrossRef](#)]
72. Jain, M.; Nilsson, R.; Sharma, S.; Madhusudhan, N.; Kitami, T.; Souza, A.L.; Kafri, R.; Kirschner, M.W.; Clish, C.B.; Mootha, V.K. Metabolite Profiling Identifies a Key Role for Glycine in Rapid Cancer Cell Proliferation. *Science* **2012**, *336*, 1040–1044. [[CrossRef](#)] [[PubMed](#)]
73. Tedeschi, P.M.; Markert, E.K.; Gounder, M.; Lin, H.; Dvorzinski, D.; Dolfi, S.C.; Chan, L.L.-Y.; Qiu, J.; DiPaola, R.S.; Hirshfield, K.M.; et al. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. *Cell Death Dis.* **2013**, *4*, e877. [[CrossRef](#)]
74. Amelio, I.; Cutruzzolá, F.; Antonov, A.; Agostini, M.; Melino, G. Serine and glycine metabolism in cancer. *Trends Biochem. Sci.* **2014**, *39*, 191–198. [[CrossRef](#)]
75. Locasale, J.W. Serine, glycine and one-carbon units: Cancer metabolism in full circle. *Nat. Rev. Cancer* **2013**, *13*, 572–583. [[CrossRef](#)] [[PubMed](#)]
76. Godwin, A.K.; Meister, A.; O’Dwyer, P.J.; Huang, C.S.; Hamilton, T.C.; Anderson, M.E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. *Proc. Natl. Acad. Sci. USA* **1992**, *89*, 3070–3074. [[CrossRef](#)]
77. Aquilano, K.; Baldelli, S.; Ciriolo, M.R. Glutathione: New roles in redox signaling for an old antioxidant. *Front. Pharmacol.* **2014**, *5*, 196. [[CrossRef](#)] [[PubMed](#)]
78. Bansal, A.; Simon, M.C. Glutathione metabolism in cancer progression and treatment resistance. *J. Cell Biol.* **2018**, *217*, 2291–2298. [[CrossRef](#)]
79. Baltruskeviciene, E.; Kazbariene, B.; Aleknavicius, E.; Krikstaponiene, A.; Venceviciene, L.; Suziedelis, K.; Stratilatovas, E.; Didziapetriene, J. Changes of reduced glutathione and glutathione S-transferase levels in colorectal cancer patients undergoing treatment. *Tumori J.* **2018**, *104*, 375–380. [[CrossRef](#)]
80. Mila-Kierzenkowska, C.; Kedziora-Kornatowska, K.; Woźniak, A.; Drewa, T.; Woźniak, B.; Drewa, S.; Krzyżyńska-Malinowska, E.; Makarewicz, R. The effect of brachytherapy on antioxidant status and lipid peroxidation in patients with cancer of the uterine cervix. *Cell. Mol. Biol. Lett.* **2004**, *9*, 511–518.
81. EKennedy, P.; Weiss, S.B. The function of cytidine coenzymes in the biosynthesis of phospholipides. *J. Biol. Chem.* **1956**, *222*, 193–214. [[CrossRef](#)]
82. Van Der Veen, J.N.; Kennelly, J.P.; Wan, S.; Vance, J.E.; Vance, D.E.; Jacobs, R.L. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. *Biochim. Biophys. Acta (BBA)—Biomembr.* **2017**, *1859*, 1558–1572. [[CrossRef](#)] [[PubMed](#)]
83. Wehrl, H.F.; Schwab, J.; Hasenbach, K.; Reischl, G.; Tabatabai, G.; Quintanilla-Martinez, L.; Jiru, F.; Chughtai, K.; Kiss, A.; Cay, F.; et al. Multimodal Elucidation of Choline Metabolism in a Murine Glioma Model Using Magnetic Resonance Spectroscopy and <sup>11</sup>C-Choline Positron Emission Tomography. *Cancer Res.* **2013**, *73*, 1470–1480. [[CrossRef](#)] [[PubMed](#)]
84. Righi, V.; Roda, J.M.; Paz, J.; Mucci, A.; Tugnoli, V.; Rodriguez-Tarduchy, G.; Barrios, L.; Schenetti, L.; Cerdan, S.; García-Martín, M.L. <sup>1</sup>H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas. *NMR Biomed.* **2009**, *22*, 629–637. [[CrossRef](#)]
85. Hattingen, E.; Bähr, O.; Rieger, J.; Blasel, S.; Steinbach, J.; Pilatus, U. Phospholipid Metabolites in Recurrent Glioblastoma: In Vivo Markers Detect Different Tumor Phenotypes before and under Antiangiogenic Therapy. *PLoS ONE* **2013**, *8*, e56439. [[CrossRef](#)]
86. Gillies, R.J.; Barry, J.A.; Ross, B.D. In Vitro and In Vivo <sup>13</sup>C and <sup>31</sup>P NMR analyses of phosphocholine metabolism in rat glioma cells. *Magn. Reson. Med.* **1994**, *32*, 310–318. [[CrossRef](#)]
87. Katz-Brull, R.; Seger, D.; Rivenson-Segal, D.; Rushkin, E.; Degani, H. Metabolic markers of breast cancer: Enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. *Cancer Res.* **2002**, *62*, 1966–1970.
88. Glunde, K.; Jacobs, M.A.; Bhujwala, Z.M. Choline metabolism in cancer: Implications for diagnosis and therapy. *Expert Rev. Mol. Diagn.* **2006**, *6*, 821–829. [[CrossRef](#)]
89. Glunde, K.; Bhujwala, Z.M.; Ronen, S.M. Choline metabolism in malignant transformation. *Nat. Rev. Cancer* **2011**, *11*, 835–848. [[CrossRef](#)]
90. Yaku, K.; Okabe, K.; Hikosaka, K.; Nakagawa, T. NAD Metabolism in Cancer Therapeutics. *Front. Oncol.* **2018**, *8*, 622. [[CrossRef](#)]
91. Lucena-Cacace, A.; Otero-Albiol, D.; Jimenez-Garcia, M.P.; Peinado-Serrano, J.; Carnero, A. NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis. *Oncotarget* **2017**, *8*, 99514–99530. [[CrossRef](#)] [[PubMed](#)]



92. Tan, B.; Young, D.A.; Lu, Z.-H.; Wang, T.; Meier, T.I.; Shepard, R.L.; Roth, K.; Zhai, Y.; Huss, K.; Kuo, M.-S.; et al. Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD<sup>+</sup> Biosynthesis, in Human Cancer Cells. *J. Biol. Chem.* **2013**, *288*, 3500–3511. [[CrossRef](#)]
93. Watson, M.; Roulston, A.; Bélec, L.; Billot, X.; Marcellus, R.; Beédard, D.; Bernier, C.; Branchaud, S.; Chan, H.; Dairi, K.; et al. The Small Molecule GMX1778 Is a Potent Inhibitor of NAD<sup>+</sup> Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors. *Mol. Cell. Biol.* **2009**, *29*, 5872–5888. [[CrossRef](#)] [[PubMed](#)]
94. Wang, B.; Hasan, K.; Alvarado, E.; Yuan, H.; Wu, H.; Chen, W.Y. NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. *Oncogene* **2010**, *30*, 907–921. [[CrossRef](#)]
95. Muruganandham, M.; Alfieri, A.A.; Matei, C.; Chen, Y.; Sukenick, G.; Schemainda, I.; Hasmann, M.; Saltz, L.; Koutcher, J.A. Metabolic Signatures Associated with a NAD Synthesis Inhibitor-Induced Tumor Apoptosis Identified by 1H-Decoupled-31P Magnetic Resonance Spectroscopy. *Clin. Cancer Res.* **2005**, *11*, 3503–3513. [[CrossRef](#)] [[PubMed](#)]
96. Che, X.-M.; Bi, T.-Q.; Liao, X.-H.; Zhang, D.-J.; Long, H.-L.; Li, H.-J.; Zhao, W. Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. *Oncol. Rep.* **2011**, *26*, 1251–1257. [[CrossRef](#)]
97. Michel, K.A.; Ragavan, M.; Walker, C.M.; Merritt, M.E.; Lai, S.Y.; Bankson, J.A. Comparison of selective excitation and multi-echo chemical shift encoding for imaging of hyperpolarized [1-13C]pyruvate. *J. Magn. Reson.* **2021**, *325*, 106927. [[CrossRef](#)]
98. Chen, H.-Y.; Aggarwal, R.; Bok, R.A.; Ohliger, M.A.; Zhu, Z.; Lee, P.; Gordon, J.W.; van Criekinge, M.; Carvajal, L.; Slater, J.B.; et al. Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: A clinical feasibility study. *Prostate Cancer Prostatic Dis.* **2020**, *23*, 269–276. [[CrossRef](#)] [[PubMed](#)]